The FDA approved taletrectinib for patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer, marking a new targeted option in a genomically defined subgroup. By focusing on ROS1-driven disease biology, the approval highlights regulators’ continued emphasis on molecular matching and on targeted therapy for oncogene-driven NSCLC. For clinicians and developers, the move intensifies competition in ROS1-positive treatment lines and increases pressure to differentiate on response durability, tolerability, and sequencing against existing targeted agents.